Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Marc H A Jansen"'
Autor:
Mohamad Hamad Saied, Laura van der Griend, Joeri W van Straalen, Nico M. Wulffraat, Sebastiaan Vastert, Marc H A Jansen
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Objective To review whether the current COVID-19 vaccines can prevent the occurrence of multisystem inflammatory syndrome in children (MIS-C) and adolescents. Methods A systematic literature review and meta-analysis were performed. The data
Externí odkaz:
https://doaj.org/article/c631c9bef4ee49be9a7221477a75719c
Autor:
Susanna J E Veringa, Dennis Biesmans, Dannis G van Vuurden, Marc H A Jansen, Laurine E Wedekind, Ilona Horsman, Pieter Wesseling, William Peter Vandertop, David P Noske, GertJan J L Kaspers, Esther Hulleman
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61512 (2013)
Pediatric high-grade gliomas (pHGG), including diffuse intrinsic pontine gliomas (DIPG), are the leading cause of cancer-related death in children. While it is clear that surgery (if possible), and radiotherapy are beneficial for treatment, the role
Externí odkaz:
https://doaj.org/article/01e687bccdfb483d9029fcb1ae9fd28e
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundAutologous hematopoietic stem cell transplantation (autoHSCT) is increasingly being recognized as a treatment option for severe refractory autoimmune diseases (AD). However, efficacy is hampered by high relapse rates. In contrast, allogenei
Externí odkaz:
https://doaj.org/article/2e8788b611f84178934d5245b386a51f
Autor:
Marc H A Jansen, Christien Rondaan, Geertje E Legger, Kirsten Minden, Yosef Uziel, Natasa Toplak, Despoina Maritsi, Lotte van den Berg, Guy A M Berbers, Patricia Bruijning, Yona Egert, Christophe Normand, Marc Bijl, Helen E Foster, Isabelle Koné-Paut, Carine Wouters, Angelo Ravelli, Ori Elkayam, Nicolaas M Wulffraat, Marloes W Heijstek
Publikováno v:
Annals of the Rheumatic Diseases, 82, 35-47. BMJ PUBLISHING GROUP
ObjectivesRecent insights supporting the safety of live-attenuated vaccines and novel studies on the immunogenicity of vaccinations in the era of biological disease-modifying antirheumatic drugs in paediatric patients with autoimmune/inflammatory rhe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70c552c7d8603414c6e39bcd088d39fb
https://doi.org/10.1136/annrheumdis-2022-222574
https://doi.org/10.1136/annrheumdis-2022-222574
Autor:
Marc H A Jansen, Femke van Wijk, Saskia R Veldkamp, Sylvia Kamphuis, Butsabong Lerkvaleekul, J. Merlijn van den Berg, E.J.H. Schatorjé, Annet van Royen-Kerkhof, Marlot van der Wal, Petra C E Hissink Muller, Wineke Armbrust, Judith Wienke, Sebastiaan J. Vastert
Publikováno v:
Rheumatology, 61, 2144-2155
Rheumatology (Oxford, England), 61(5), 2144-2155. Oxford University Press
Rheumatology, 61(5), 2144-2155. Oxford University Press
Rheumatology, 61, 5, pp. 2144-2155
Rheumatology (United Kingdom), 61(5), 2144-2155. Oxford University Press
Rheumatology (Oxford, England), 61(5), 2144-2155. Oxford University Press
Rheumatology, 61(5), 2144-2155. Oxford University Press
Rheumatology, 61, 5, pp. 2144-2155
Rheumatology (United Kingdom), 61(5), 2144-2155. Oxford University Press
Objective JDM is a rare chronic immune-mediated inflammatory disease with a predominant role for type I IFN responses. We aimed to determine the potential of Siglec-1 expression on monocytes as a novel IFN-inducible biomarker for disease activity mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38828807500d20f0ff6e3ef9e964b246
http://hdl.handle.net/2066/283123
http://hdl.handle.net/2066/283123
Autor:
Fatma E El-Khouly, Sophie E. M. Veldhuijzen van Zanten, Esther Sanchez Aliaga, W. Peter Vandertop, Dannis G. van Vuurden, N. Harry Hendrikse, Dewi P. Bakker, Gertjan J.L. Kaspers, Marc H. A. Jansen
Publikováno v:
Journal of Neuro-Oncology, 153(2), 263-271. Kluwer Academic Publishers
Journal of Neuro-Oncology, 153(2), 263-271. Kluwer Academic
Journal of neuro-oncology, 153(2), 263-271. Kluwer Academic Publishers
Journal of Neuro-Oncology
El-Khouly, F E, Veldhuijzen van Zanten, S E M, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Hendrikse, N H, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2021, ' A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 153, no. 2, pp. 263-271 . https://doi.org/10.1007/s11060-021-03763-1
Journal of Neuro-Oncology, 153(2), 263-271. Kluwer Academic
Journal of neuro-oncology, 153(2), 263-271. Kluwer Academic Publishers
Journal of Neuro-Oncology
El-Khouly, F E, Veldhuijzen van Zanten, S E M, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Hendrikse, N H, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2021, ' A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 153, no. 2, pp. 263-271 . https://doi.org/10.1007/s11060-021-03763-1
Introduction This study investigates the safety, tolerability, and preliminary efficacy of combined treatment with VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan, and EGFR inhibitor erlotinib in children with progressive diffuse int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b5cd964c19a4c2c73e81b5e280ec0d5
https://research.vumc.nl/en/publications/99c311f6-a6ec-4c49-9b55-1e02e59d3bb6
https://research.vumc.nl/en/publications/99c311f6-a6ec-4c49-9b55-1e02e59d3bb6
Autor:
Esther Sanchez Aliaga, C. Michel Zwaan, Fatma E El-Khouly, Sophie E. M. Veldhuijzen van Zanten, W. Peter Vandertop, Dannis G. van Vuurden, Cornelis J.A. Haasbeek, Gertjan J.L. Kaspers, Marc H. A. Jansen, Dewi P. Bakker, Nicole I. Wolf
Publikováno v:
Journal of Neuro-Oncology
Journal of Neuro-Oncology, 135(2), 307-315. Kluwer Academic Publishers
Veldhuijzen van Zanten, S E M, El-Khouly, F E, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Haasbeek, C J A, Wolf, N I, Zwaan, C M, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2017, ' A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 135, no. 2, pp. 307-315 . https://doi.org/10.1007/s11060-017-2575-9
Journal of Neuro-Oncology, 135(2), 307-315. Kluwer Academic
Journal of neuro-oncology, 135(2), 307-315. Kluwer Academic Publishers
Journal of Neuro-Oncology, 135(2), 307-315. Kluwer Academic Publishers
Veldhuijzen van Zanten, S E M, El-Khouly, F E, Jansen, M H A, Bakker, D P, Sanchez Aliaga, E, Haasbeek, C J A, Wolf, N I, Zwaan, C M, Vandertop, W P, van Vuurden, D G & Kaspers, G J L 2017, ' A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma ', Journal of Neuro-Oncology, vol. 135, no. 2, pp. 307-315 . https://doi.org/10.1007/s11060-017-2575-9
Journal of Neuro-Oncology, 135(2), 307-315. Kluwer Academic
Journal of neuro-oncology, 135(2), 307-315. Kluwer Academic Publishers
The purpose of this phase I/II, open-label, single-arm trial is to investigate the safety, tolerability, maximum tolerated dose and preliminary efficacy of the potential radiosensitizer gemcitabine, administered concomitantly to radiotherapy, in chil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d28103ec82d4e56c5af410b3932e028d
https://doi.org/10.1007/s11060-017-2575-9
https://doi.org/10.1007/s11060-017-2575-9
Autor:
Danielle J. Vugts, Gertjan J.L. Kaspers, Carla F. M. Molthoff, Pieter Wesseling, W. Peter Vandertop, Marc H. A. Jansen, Dannis G. van Vuurden, Angel M. Carcaboso, Naomi Petersen, Tonny Lagerweij, Esther Hulleman, Guus A.M.S. van Dongen, David P. Noske, Susanna J.E. Veringa, Viola Caretti, A. Charlotte P. Sewing
Publikováno v:
Molecular cancer therapeutics, 15(9), 2166-2174. American Association for Cancer Research Inc.
Molecular Cancer Therapeutics, 15, 2166-74
Molecular Cancer Therapeutics, 15, 9, pp. 2166-74
Molecular Cancer Therapeutics, 15(9), 2166-2174. American Association for Cancer Research Inc.
Jansen, M H A, Lagerweij, T, Sewing, A C P, Vugts, D J, van Vuurden, D G, Molthoff, C F M, Caretti, V, Veringa, S J E, Petersen, N, Carcaboso, A M, Noske, D P, Vandertop, W P, Wesseling, P, van Dongen, G A M S, Kaspers, G J L & Hulleman, E 2016, ' Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma : Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models ', Molecular Cancer Therapeutics, vol. 15, no. 9, pp. 2166-2174 . https://doi.org/10.1158/1535-7163.MCT-15-0558
Molecular Cancer Therapeutics, 15, 2166-74
Molecular Cancer Therapeutics, 15, 9, pp. 2166-74
Molecular Cancer Therapeutics, 15(9), 2166-2174. American Association for Cancer Research Inc.
Jansen, M H A, Lagerweij, T, Sewing, A C P, Vugts, D J, van Vuurden, D G, Molthoff, C F M, Caretti, V, Veringa, S J E, Petersen, N, Carcaboso, A M, Noske, D P, Vandertop, W P, Wesseling, P, van Dongen, G A M S, Kaspers, G J L & Hulleman, E 2016, ' Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma : Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models ', Molecular Cancer Therapeutics, vol. 15, no. 9, pp. 2166-2174 . https://doi.org/10.1158/1535-7163.MCT-15-0558
The role of the VEGF inhibitor bevacizumab in the treatment of diffuse intrinsic pontine glioma (DIPG) is unclear. We aim to study the biodistribution and uptake of zirconium-89 (89Zr)-labeled bevacizumab in DIPG mouse models. Human E98-FM, U251-FM g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ffa8c39b61b920aee796de255a741a
https://hdl.handle.net/2066/172023
https://hdl.handle.net/2066/172023
Autor:
Esther Sanchez Aliaga, Marc H. A. Jansen, Gertjan J.L. Kaspers, W. Peter Vandertop, Dannis G. van Vuurden, Sophie E. M. Veldhuijzen van Zanten
Publikováno v:
Expert Review of Anticancer Therapy, 15(2), 157-64. Taylor and Francis Ltd.
Veldhuijzen van Zanten, S E M, Jansen, M H A, Sanchez Aliaga, E, van Vuurden, D G, Vandertop, W P & Kaspers, G J L 2015, ' A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands ', Expert Review of Anticancer Therapy, vol. 15, no. 2, pp. 157-64 . https://doi.org/10.1586/14737140.2015.974563
Veldhuijzen van Zanten, S E M, Jansen, M H A, Sanchez Aliaga, E, van Vuurden, D G, Vandertop, W P & Kaspers, G J L 2015, ' A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands ', Expert Review of Anticancer Therapy, vol. 15, no. 2, pp. 157-64 . https://doi.org/10.1586/14737140.2015.974563
INTRODUCTION: Children with diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis, with a median overall survival of 9 months. Our aims are to determine the incidence of DIPG in the Netherlands and to identify points for improvement in clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f6608d89bb14c31e53112408b6e51ad
https://doi.org/10.1586/14737140.2015.974563
https://doi.org/10.1586/14737140.2015.974563
Autor:
Guus A.M.S. van Dongen, Sophie E. M. Veldhuijzen van Zanten, Gertjan L. Kaspers, Marc C. Huisman, Marc H. A. Jansen, Danielle J. Vugts, Otto S. Hoekstra, Dannis G. van Vuurden
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 58(5), 711-716
Jansen, M H, Veldhuijzen van Zanten, S E M, van Vuurden, D G, Huisman, M C, Vugts, D J, Hoekstra, O S, van Dongen, G A & Kaspers, G-J L 2017, ' Molecular Drug Imaging : 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 58, no. 5, pp. 711-716 . https://doi.org/10.2967/jnumed.116.180216
Jansen, M H, Veldhuijzen van Zanten, S E M, van Vuurden, D G, Huisman, M C, Vugts, D J, Hoekstra, O S, van Dongen, G A & Kaspers, G-J L 2017, ' Molecular Drug Imaging : 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 58, no. 5, pp. 711-716 . https://doi.org/10.2967/jnumed.116.180216
Predictive tools for guiding therapy in children with brain tumors are urgently needed. In this first molecular drug imaging study in children, we investigated whether bevacizumab can reach tumors in children with diffuse intrinsic pontine glioma (DI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a865f20b680ee2c758da2219818338d9
https://research.vumc.nl/en/publications/86a5ddc6-df3c-471c-a99b-26f538de5950
https://research.vumc.nl/en/publications/86a5ddc6-df3c-471c-a99b-26f538de5950